The Influenzavirus A Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Influenzavirus A Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Influenzavirus A Infections. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Influenzavirus A Infections and features dormant and discontinued products.

GlobalData tracks 240 drugs in development for Influenzavirus A Infections by 184 companies/universities/institutes. The top development phase for Influenzavirus A Infections is preclinical with 102 drugs in that stage. The Influenzavirus A Infections pipeline has 180 drugs in development by companies and 60 by universities/ institutes. Some of the companies in the Influenzavirus A Infections pipeline products market are: National Institute of Allergy and Infectious Diseases, Moderna and Sanofi.

The key targets in the Influenzavirus A Infections pipeline products market include Hemagglutinin HA (HA), Hemagglutinin, and Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18).

The key mechanisms of action in the Influenzavirus A Infections pipeline product include Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18) Inhibitor with nine drugs in Phase II. The Influenzavirus A Infections pipeline products include 13 routes of administration with the top ROA being Intramuscular and 22 key molecule types in the Influenzavirus A Infections pipeline products market including Small Molecule, and Subunit Vaccine.

Influenzavirus A Infections overview

Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza A virus are called hemagglutinin (H) and neuraminidase (N). Different virus subtypes have differences in their surface proteins.

For a complete picture of Influenzavirus A Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.